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Natural products (NPs) have proven to be an invaluable source of new chemotherapies yet very few have
been explored to source small molecule carbonic anhydrase (CA) inhibitors. CA enzymes underpin phys-
iological pH and are critical to the progression of several diseases including cancer. The present study is
the first to more widely investigate NP coumarins for CA inhibition following the recent discovery of a NP
coumarin CA inhibitor. We assembled a NP library comprising 24 plant coumarins (compounds 4–27) and
three ascidian coumarins (compounds 28–30) that together provide a diverse collection of structures
containing the coumarin pharmacophore. This library was then evaluated for inhibition of six human
CA isozymes (CAs I, II, VII, IX, XII and XIII) and a broad range of inhibition and isozyme selectivity profiles
were evident. Our findings provide a platform to support further evaluation of NPs for the discovery of
new chemotypes that inhibit disease relevant CA enzymes.
 2012 Elsevier Ltd. All rights reserved.1. Introduction
Carbonic anhydrase enzymes (CA, EC 4.2.1.1) catalyze the
reversible hydration of carbon dioxide (CO2) to generate bicarbon-
ate anion (HCO3) and a proton (H+).1,2 Our knowledge of the phys-
iological impact of this reaction has grown significantly in recent
years, with CA now validated as a target for cancer therapy inter-
vention by inhibition of extracellular CA IX3 and XII.4 Several CA
isozymes, including cytosolic CA VII5 and CA XIII,6,7 are potential
targets in other conditions where pH homeostasis is critical.8 The
CA enzyme active site comprises a tetrahedral Zn2+ cation that
plays both a structural and catalytic role for the enzyme9 and this
metal is the implied target for medicinal chemistry. As a conse-
quence almost all reported small molecule CA inhibitors comprise
a zinc binding group (ZBG) of which the primary sulfonamide moi-
ety (–SO2NH2) is the foremost example for CA inhibition. A core
role of medicinal chemists in the CA field is to develop novel,
drug-like, isozyme selective small molecule inhibitors for human
CA isozymes. Natural products (NPs) comprise a vast collection of
diverse chemical structures and have proven an invaluable source
of new chemotherapies10–13 yet very few NPs have been explored
to source novel CA inhibitors.14 NPs that comprise a primaryll rights reserved.
nhydrase; ZBG, zinc binding
sorption distribution metab-
n mass spectrometry.
x: +39 055 4573385 (C.T.S.);
Supuran), s.poulsen@griffith.sulfonamide moiety in their structure are rare and have not been
investigated for CA inhibition, Figure 1.15,16 As the primary sulfon-
amide moiety is poorly represented in NP chemical space, this
space presents a rich source of potential new chemotypes towards
discovery of alternate CA inhibitors.
Plant NPs have been the basis of traditional medicine for thou-
sands of years and continue to actively contribute to contemporary
drug discovery.13 The significance of NPs in drug discovery is most
evident in the anti-cancer17 and antibiotic18,19 therapeutic areas.
Coumarin compounds are abundant secondary metabolites in
plants and are found in lesser amounts in microorganisms and ani-
mal sources. Plant coumarins are phytoalexins, defense com-
pounds produced when the plant is under threat from other
organisms, and have attracted interest owing to a range of biolog-
ical activities including anti-microbial, anti-viral, anti-cancer, anti-
oxidant and anti-inflammatory properties.20 A recent review high-
lights the growing interest in the coumarin class of compound toFigure 1. NPs that comprise a primary sulfonamide moiety in their structure, such
as () altemicidin and psammaplin C, are rare and have not been investigated for
CA inhibition.
Figure 2. Compound 1, the first reported natural product coumarin CA inhibitor;
compound 2, coumarin—the simplest structure of the coumarin compound class
and a weak CA inhibitor; the CA-catalyzed hydrolysis product of coumarin 1, the
cinnamic acid derivative compound 3.
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riched Leionema ellipticum (Rutaceae) extracts were screened using
electrospray ionization mass spectrometry (ESI MS) for binding to
bovine CA II (bCA II).22 From this study the coumarin, 6-(1S-hydro-
xy-3-methylbutyl)-7-methoxy-2H-chromen-2-one (1) was identi-
fied as a ligand for bCA II as it formed a noncovalent complex
that could be detected by ESI MS (Fig. 2). It was subsequently dem-
onstrated that 1 differentially inhibits a spectrum of human CAs in
a time dependent manner, and with much higher activity than cou-
marin 2, the simplest NP coumarin (Fig. 2).23 As coumarin com-
pounds lack the classic sulfonamide ZBG of known smallFigure 3. Natural product coumarin library sourmolecule CA inhibitors it was of interest to understand how this
NP binds to CAs. Using protein X-ray crystallography we observed
the hydrolysis product of 1, the cinnamic acid derivative 3, span-
ning the entrance to the hCA II active site following incubation of
1 with hCA II (Fig. 2).23 Esterase activity is known for CAs24,25
and the observation of cinnamic acid 3 rather than coumarin 1,
although unexpected, could be rationalized as a consequence of
hCA II esterase activity leading to hydrolysis of the lactone of 1.
Since the discovery of the NP coumarin 1 synthetic libraries of
coumarins and thiocoumarins have been prepared and evaluated
as CA inhibitors.26–28 These synthetic compounds have supported
our findings with the NP coumarin, namely maximum inhibition
is observed following 6 h incubation with the CA enzyme (while
15 min incubation is usual for classical sulfonamide CA inhibitors).
The extended incubation period is related to the kinetics of couma-
rin hydrolysis. Recently a series of substituted coumarins incorpo-
rating a selection of glycosyl moieties were synthesized.3 These
glycoconjugates were very weak inhibitors of off-target CA I
and II, while several strongly inhibited tumor-associated CA IX
and XII.3 One glycosyl coumarin inhibited the growth of primary
tumors in the highly aggressive 4T1 syngeneic mouse mammaryced from Nature Bank,33 compounds 4–30.
Table 1
Inhibition data for coumarin 2 and NP coumarins 4–30 against human CA isozymes
(CA I, II, VII, IX, XII and XIII) following a 6 h incubation time with enzyme
Compd Ki (lM)a,b
CA I CA II CA VII CA IX CA XII CA XIII
2 3.10 9.20 >1000 >1000 >1000 >1000
4 7.66 >100 0.65 0.62 0.79 45.0
5 8.46 >100 8.98 0.78 0.77 29.3
6 9.31 50.7 8.87 0.83 0.81 21.0
7 59.2 63.4 9.03 0.89 0.60 27.4
8 9.75 >100 7.82 0.60 0.83 9.62
9 7.81 >100 3.69 4.03 0.70 6.10
10 21.5 >100 9.18 7.51 25.7 8.36
11 7.71 >100 6.27 0.74 0.96 3.15
12 9.21 49.3 9.31 0.86 8.35 >100
13 5.60 >100 8.11 3.50 9.10 5.91
14 9.89 >100 5.56 0.85 7.84 95.7
15 4.86 94.3 4.32 0.61 7.70 9.73
16 10.56 >100 8.71 0.96 4.05 17.8
17 0.0097 >100 9.28 6.58 18.2 4.24
18 4.31 9.65 7.01 0.76 0.83 3.32
19 36.4 >100 4.53 0.85 9.12 7.26
20 14.0 >100 23.8 7.37 4.14 5.27
21 5.04 >100 3.87 0.37 7.45 9.80
22 5.93 >100 9.11 8.72 0.78 8.43
23 9.11 >100 8.85 8.12 7.44 8.89
24 5.84 >100 >100 0.67 7.39 4.06
25 7.52 78.9 6.92 9.75 0.77 6.35
26 68.2 >100 8.79 79.8 8.15 4.24
27 44.1 >100 8.58 17.4 7.42 5.97
28 6.45 >100 14.5 3.22 9.07 4.63
29 40.1 >100 58.3 6.33 8.51 3.70
30 6.55 >100 78.4 3.27 1.79 4.24
a This inhibition data was acquired using a stopped-flow assay that monitors the
CA-catalyzed hydration of CO2.61 Errors in the range of ±5% of the reported value,
from three determinations.
b All proteins were recombinant.
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tro.3 Finally, a small selection of other plant NPs have been evalu-
ated as CA inhibitors, most notably phenolic NPs14,29–32 that
displayed interesting CA inhibition characteristics.
Inspired by the success of NPs in contributing new small mole-
cule therapeutics together with the promising findings that the
coumarin class of compounds act as CA inhibitors and have anti-
tumor activity3,23 we accessed Nature Bank (from which coumarin
1was discovered) to source further NP coumarins. Nature Bank is a
unique drug discovery resource that consists of >50,000 biota sam-
ples collected from Australia, China and Papua New Guinea along
with biota extracts, semi-purified fractions and pure compounds.33
A substructure search of the Nature Bank pure compound reposi-
tory against the bare coumarin scaffold 2 was performed and a
set of 81 coumarins were initially identified. From this set a subset
of 27 coumarins were sourced in sufficient quantity and purity for
follow up evaluation as CA inhibitors. These NP coumarins, com-
pounds 4–30 (Fig. 3), form the basis of the present manuscript
wherein we describe the CA inhibition against six human CA iso-
zymes and evaluate the drug-like properties of this coumarin
library.
2. Results and discussion
2.1. Compound library
TheNP coumarin library of this study comprises 24 plant couma-
rins (compounds 4–27) and three ascidian coumarins (compounds
28–30), all of which have previously been characterized. Specifi-
cally, the plant NPs comprise avicennin 4,34,35 trans-avicennol
5,36,37 calanolide B 6,33,38 dihydrogeiparvarin 7,39 geiparvarin
8,39,40 dehydromarmin 9,39 xanthyletin 10,41 xanthoxyletin 11,36,41
ceylantin 12,42 alloxanthoxyletin 13,41 fraxidin 14,43 fraxin 15,44
scopoletin 16,45 6,7,8-trimethoxycoumarin 17,46 5,7,8-trimethoxy-
coumarin 18,46 7-hydroxy-8-methoxycoumarin 19,45 isoscopoletin
20,47 fraxoside 21,48 scopolin 22,49 murralongin 23,50 (+)-isomurr-
alonginol nicotinate 24,51 isophellodenol C 25,52 ellagic acid 26,53
and nasutin B 27.54 The ascidian NP coumarins include lamellarins
E 28,55 B 29,56 and G 8-sulfate 30.57 A variety of bioactivities have
been reported for these coumarins, for example calanolide B 6, iso-
lated from the tropical rainforest tree Calophyllum lanigerum,
displayed protection against HIV-1 replication and cytopathicity
(EC50 = 0.4 lM).38 Dihydrogeiparvarin 7 and geiparvan 8, both
isolated from Geijera paruiflora,39,40 possessed significant in vitro
activity against human carcinoma of the nasopharynx.58,59 Xanth-
oxyletin 11,36,41 purified from a variety of Citrus species, acted as a
DNA-damaging agent,60 while several synthetic derivatives have
been shown to exhibit toxicity towards L-1210 leukemia cells with
IC50 values ranging from 0.9 to 60.3 lM.60
2.2. Carbonic anhydrase inhibition
The inhibition activity data for coumarin 2 and NP coumarins
4–30 against human CA I and II (off-target isozymes), as well CA
VII, IX, XII and XIII (isozymes of interest in therapeutic drug devel-
opment) is presented in Table 1.
Coumarin 2, the simplest coumarin, is not an appreciable inhib-
itor of CA VII, IX, XII or XIII however it is a weak inhibitor of off-tar-
get CA I and CA II with Kis of 3.1 and 9.2 lM, respectively. The
complexity and diversity of structures within this NP coumarin li-
brary far exceeds that described for synthetic coumarins that have
been assessed for CA inhibition. These NP coumarins are substi-
tuted at any of six available sites, with many fused to form tricyclic,
tetracyclic or larger ring systems. This diversity does not readily al-
low simple structure–activity relationships (SARs) to be defined,however several trends surrounding CA inhibition are evident.
Most obvious is that the NP coumarin library members are very
weak CA II inhibitors, most have Kis > 100 lM, the only exception
being the trimethoxycoumarin 18 (Ki = 9.65 lM). When compared
to the structurally related methoxy/hydroxy coumarins 14–17, 19
and 20, compound 18 differs only in the pattern of substituents,
this SAR indicates that it may be a combination of interacting sub-
stituents that directs the CA inhibition profile at CA II. At CA I, VII,
IX, XII and XIII many of the NP coumarins have Kis in the range of
1–10 lM, this tight grouping of Kis reflects minimal isozyme selec-
tivity for these coumarins, however there are a few outliers to this
general trend and these compounds represent interesting struc-
tures owing to their CA isozyme selectivity characteristics. At CA
I there was one stand out compound being compound 17, a nano-
molar CA I inhibitor. This trimethoxy coumarin is the most potent
of any of the NP coumarins across the six CA isozymes of the pres-
ent study. At CA XIII there were no submicromolar inhibitors while
the dimethoxy coumarin 12 was the weakest of the CA XIII inhib-
itors (Ki > 100 lM). Similar to CA I and II the relationship of meth-
oxy substituents for CA XIII binding appeared important for
defining the inhibition characteristics, with the structurally related
coumarins 10 and 11 10-fold better inhibitors than the methoxy
coumarin 12. At CA VII three coumarins, compounds 24, 29 and
30, exhibited weaker inhibition (Kis 58 to >100 lM) than the
remainder, interestingly these include three of the four nitrogen
containing coumarins. Around half of the NP coumarins have sub-
micromolar inhibition of the validated cancer-associated isozymes
CA IX and XII, some of these coumarins (4, 5, 6, 7, 8, 11 and 18) are
submicromolar at both CA IX and XII, while the remainder are sub-
micromolar at either CA IX (12, 14–16, 19, 21 and 24) or CA XII (9,
22 and 25). This subset of NP coumarins have viable CA IX and/or
1542 R. A. Davis et al. / Bioorg. Med. Chem. 21 (2013) 1539–1543XII selectivity characteristics that warrant further studies in cell-
based models of CA in cancer.
2.3. Property profiling
Software tools for multiparameter profiling are inexpensive and
provide rapid feedback, and when used with an awareness of the
limitations around accuracy of prediction may provide insight into
drug-like properties of a compound class to guide the direction of
follow-on studies and flag potential compound liabilities.62 Qik-
Prop (Schrödinger Suite 2009) is a Pharma industry gold standard
software package that allows the calculation of compound proper-
ties and prediction of absorption, distribution, metabolism and
elimination (ADME) properties.63 For the NP coumarins 4–30 a
selection of predicted property values generated by QikProp are
provided in the supplementary data. Of note is that these coumarin
NPs have predicted property and descriptor values that are all
within the 95% range of values for known drugs.64 Reactive Mi-
chael acceptors are a general structural alert in drug discovery,
however it has been demonstrated that simple coumarins exhibit
poor protein binding characteristics compared to other carbonyl
containing Michael acceptors.65,66 This poorer reactivity of the cou-
marin double bond compared with other Michael acceptors, has
been attributed to it being part of a pseudoaromatic system.67
3. Conclusions
Following from the recent discovery that coumarins are time
dependent CA inhibitors (owing to CA-mediated lactone hydroly-
sis) this study is the first to more fully investigate NP coumarins
for CA inhibition. A NP coumarin library, compounds 4–30, com-
prising a diverse collection of structures containing the coumarin
pharmacophore was sourced from Nature Bank.33 This coumarin li-
brary provided a rich collection of stereochemistry and structural
diversity, yet significantly the compounds lack the sulfonamide
ZBG that is typical of classical CA inhibitors. These coumarins
exhibited CA inhibition profiles consistent with compounds useful
for the development of small molecules that act with an alternate
mechanism of CA enzyme inhibition compared to classical CA
inhibitors. Our findings provide a platform to support the further
evaluation of NPs for discovery of novel chemotypes with im-
proved drug-like properties for inhibition of disease relevant CA
enzymes.
4. Experimental
4.1. Chemistry
Compounds 4–30 were all isolated from plant or marine inver-
tebrates archived in Nature Bank,33 which is located at the Eskitis
Institute, Griffith University. All compounds were identified as pre-
viously reported NPs following spectroscopic and spectrometric
data analysis and comparison with literature values.33–57 Prior to
biological evaluation all compounds were subjected to purity anal-
ysis by 1H NMR spectroscopy and shown to be >95%.
4.2. CA inhibition assay
An SX.18MV-R Applied Photophysics stopped-flow instrument
has been used for assaying the CA I, II, VII, IX, XII and XIII CO2
hydration activity.61 Phenol red (at a concentration of 0.2 mM)
has been used as indicator, working at the absorbance maximum
of 557 nM, with 10 mM Hepes (pH 7.5) as buffer, 0.1 M NaClO4
(for maintaining constant the ionic strength—this anion is not
inhibitory), following the CA-catalyzed CO2 hydration reaction fora period of 10–100 s. Saturated CO2 solutions in water at 20 C
were used as substrate. Stock solutions of inhibitors were prepared
at a concentration of 10–50 mM (in the assay buffer) and dilutions
up to 1 nM were done with the assay buffer mentioned above.
Inhibitor and enzyme solutions were preincubated together for
6 h at room temperature prior to assay, in order to allow for the
formation of the enzyme-inhibitor complex. The inhibition con-
stants were obtained by non-linear least-squares methods using
PRISM 3. The curve-fitting algorithm allowed us to obtain the
IC50 values, working at the lowest concentration of substrate of
1.7 mM), from which Ki values were calculated by using the
Cheng–Prusoff equation. The catalytic activity (in the absence of
inhibitors) of these enzymes was calculated from Lineweaver–Burk
plots and represents the mean from at least three different deter-
minations. Enzyme concentrations were CA I, 15; CA II, 8.6; CA
VII, 12; CA IX, 6.9; CA XII, 14; CA XII, 16 nM. All enzymes in this
study were recombinant.
Acknowledgments
This research was financed by the Australian Research Council
(Grant number DP110100071 to S.-A.P.), and Grants of the 6th
and 7th Framework Programme of the European Union (DeZnIT
project and Metoxia project). We thank Ron Quinn for access to
coumarins 4–30, which form part of the Eskitis Institute’s Nature
Bank pure compound library. We thank Marc Campitelli for assis-
tance with QikProp software.
References and notes
1. Supuran, C. T. Nat. Rev. Drug Disc. 2008, 7, 168.
2. Krishnamurthy, V. M.; Kaufman, G. K.; Urbach, A. R.; Gitlin, I.; Gudiksen, K. L.;
Weibel, D. B.; Whitesides, G. M. Chem. Rev. 2008, 108, 946.
3. Touisni, N.; Maresca, A.; McDonald, P. C.; Lou, Y.; Scozzafava, A.; Dedhar, S.;
Winum, J.-Y.; Supuran, C. T. J. Med. Chem. 2011, 54, 8271.
4. Neri, D.; Supuran, C. T. Nat. Rev. Drug Disc. 2011, 10, 767.
5. Bootorabi, F.; Haapasalo, J.; Smith, E.; Haapasalo, H.; Parkkila, S. Health 2011, 3,
6.
6. Lehtonen, J. M.; Shen, B.; Vihinen, M.; Casini, A.; Scozzafava, A.; Supuran, C. T.;
Parkkila, A.-K.; Saarnio, J.; Kivela, A. J.; Waheed, A.; Sly, W. S.; Parkkila, S. J. Biol.
Chem. 2004, 279, 2719.
7. Di Fiore, A.; Monti, S. M.; Hilvo, M.; Parkkila, S.; Romano, V.; Scaloni, A.; Pedone,
C.; Scozzafava, A.; Supuran, C. T.; De Simone, G. Proteins 2008, 164.
8. Hassan, M. I.; Shajee, B.; Waheed, A.; Ahmad, F.; Sly, W. S. Bioorg. Med. Chem.
2012. Epub ahead of print.
9. Alterio, V.; Di Fiore, A.; D’Ambrosio, K.; Supuran, C. T.; De Simone, G. Chem. Rev.
2012, Articles ASAP, doi: http://dx.doi.org/10.1021/cr200176r.
10. Newman, D. J.; Cragg, G. M. J. Nat. Prod. 2007, 70, 461.
11. Newman, D. J.; Cragg, G. M. Future Med. Chem. 2009, 1, 1415.
12. Lam, K. S. Trends Microbiol. 2007, 15, 279.
13. Lachance, H.; Wetzel, S.; Kumar, K.; Waldmann, H. J. Med. Chem. 2012, 55, 5989.
14. Supuran, C. T. Mol. Div. 2011, 15, 305.
15. Takahashi, A.; Kurasawa, S.; Ikeda, D.; Okami, Y.; Takeuchi, T. J. Antibiot. 1989,
42, 1556.
16. Jimenez, C.; Crews, P. Tetrahedron 1991, 47, 2097.
17. Mann, J. Nat. Rev. Cancer 2002, 2, 143.
18. Butler, M. S.; Cooper, M. A. J. Antibiot. 2011, 64, 413.
19. Butler, M. S.; Buss, A. D. Biochem. Pharmacol. 2006, 71, 919.
20. Borges, F.; Roleira, F.; Milhazes, N.; Santana, L.; Uriarte, E. Curr. Med. Chem.
2005, 12, 887.
21. Kontogiorgis, C.; Detsi, A.; Hadjipavlou-Litina, D. Expert Opin. Ther. Pat. 2012,
22, 437.
22. Vu, H.; Pham, N. B.; Quinn, R. J. J. Biomol. Screen. 2008, 13, 265.
23. Maresca, A.; Temperini, C.; Vu, H.; Pham, N. B.; Poulsen, S.-A.; Scozzafava, A.;
Quinn, R. J.; Supuran, C. T. J. Am. Chem. Soc. 2009, 131, 3057.
24. Lopez, M.; Vu, H.; Wang, C. K.; Wolf, M. G.; Groenhof, G.; Innocenti, A.; Supuran,
C. T.; Poulsen, S.-A. J. Am. Chem. Soc. 2011, 133, 18452.
25. Krebs, J. F.; Ippolito, J. A.; Christianson, D. W.; Fierke, C. A. J. Biol. Chem. 1993,
268, 27458.
26. Carta, F.; Maresca, A.; Scozzafava, A.; Supuran, C. T. Bioorg. Med. Chem. 2012, 20,
2266.
27. Maresca, A.; Supuran, C. T. Bioorg. Med. Chem. Lett. 2010, 20, 4511.
28. Maresca, A.; Temperini, C.; Pochet, L.; Masereel, B.; Scozzafava, A.; Supuran, C.
T. J. Med. Chem. 2009, 53, 335.
29. Davis, R. A.; Hofmann, A.; Osman, A.; Hall, R. A.; Mühlschlegel, F. A.; Vullo, D.;
Innocenti, A.; Supuran, C. T.; Poulsen, S. A. J. Med. Chem. 2011, 54, 1682.
R. A. Davis et al. / Bioorg. Med. Chem. 21 (2013) 1539–1543 154330. Davis, R. A.; Innocenti, A.; Poulsen, S.-A.; Supuran, C. T. Bioorg. Med. Chem. 2010,
18, 14.
31. Innocenti, A.; Sarikaya, S. B. O.; Gulcin, I.; Supuran, C. T. Bioorg. Med. Chem.
2010, 18, 2159.
32. Poulsen, S.-A.; Davis, R. A.; Keys, T. G. Bioorg. Med. Chem. 2006, 14, 510.
33. http://www.nature-bank.com.au.
34. Sarker, S. D.; Armstrong, J. A.; Gray, A. I.; Waterman, P. G. Biochem. Syst. Ecol.
1994, 22, 641.
35. Sarker, S. D.; Armstrong, J. A.; Waterman, P. G. Biochem. Syst. Ecol. 1994, 22, 863.
36. Gray, A. I.; Waigh, R. D.; Waterman, P. G. Phytochemistry 1977, 16, 1017.
37. Sultana, N.; Sarker, S. D.; Armstrong, J. A.; Wilson, P. G.; Waterman, P. G.
Biochem. Syst. Ecol. 2003, 31, 681.
38. Kashman, Y.; Gustafson, K. R.; Fuller, R. W.; Cardellina Ii, J. H.; McMahon, J. B.;
Currens, M. J.; Buckheit, R. W., Jr.; Hughes, S. H.; Cragg, G. M.; Boyd, M. R. J. Med.
Chem. 1992, 35, 2735.
39. Dreyer, D. L.; Lee, A. Phytochemistry 1972, 11, 763.
40. Lahey, F. N.; MacLeod, J. K. Aust. J. Chem. 1967, 20, 1943.
41. Mujumdar, R. B.; Rathi, S. S.; Rao, A. V. R. Indian J. Chem., Sect B 1977, 15B, 200.
42. Ahmad, J.; Shamsuddin, K. M.; Zaman, A. Phytochemistry 1984, 23, 2098.
43. Spath, E.; Dobrovolny, E. Ber. Dtsch. Chem. Ges. B 1938, 71B, 1831.
44. Morikawa, T.; Tao, J.; Toguchida, I.; Matsuda, H.; Yoshikawa, M. J. Nat. Prod.
2003, 66, 86.
45. Barbera, O.; Alberto Marco, J.; Sanz, J. F.; Sanchez-Parareda, J. Phytochemistry
1986, 25, 2357.
46. Gonzalez, A. G.; Diaz Chico, E.; Lopez Dorta, H.; Medina, J. M.; Rodriguez Luis, F.
An. Quim. 1977, 73, 1015.
47. Zhang, W.-D.; Kong, D.-Y.; Li, H.-T.; Gu, Z.-B.; Qin, L.-P. Zhongguo Yiyao Gongye
Zazhi 1998, 29, 498.48. Lin, S.; Wang, S.; Liu, M.; Gan, M.; Li, S.; Yang, Y.; Wang, Y.; He, W.; Shi, J. J. Nat.
Prod. 2007, 70, 817.
49. Wu, T. S.; Tsang, Z. J.; Wu, P. L.; Lin, F. W.; Li, C. Y.; Teng, C. M.; Lee, K. H. Bioorg.
Med. Chem. 2001, 9, 77.
50. Raj, K.; Misra, S. C.; Kapil, R. S.; Popli, S. P. Phytochemistry 1976, 15, 1787.
51. Ito, C.; Furukawa, H. Heterocycles 1987, 26, 2959.
52. Nakamori, T.; Taniguchi, M.; Shibano, M.; Wang, N.-H.; Baba, K. J. Nat. Med.
2008, 62, 403.
53. Bhatia, I. S.; Bhatia, M. S.; Sharma, R. S.; Bajaj, K. L. Indian J. Chem. 1972, 10, 959.
54. Rao, K. V. Planta Med. 1974, 25, 166.
55. Lindquist, N.; Fenical, W.; Van Duyne, G. D.; Clardy, J. J. Org. Chem. 1988, 53,
4570.
56. Andersen, R. J.; Faulkner, D. J.; He, C. H.; Van Duyne, G. D.; Clardy, J. J. Am. Chem.
Soc. 1985, 107, 5492.
57. Davis, R. A.; Carroll, A. R.; Pierens, G. K.; Quinn, R. J. J. Nat. Prod. 1999, 62, 419.
58. Padmawinata, K. Acta Pharm. Hung. 1973, 4, 1.
59. Jerris, P. J.; Smith, A. B., III J. Org. Chem. 1981, 46, 577.
60. Gunatilaka, L.; Kingston, D.; Wijeratne, K.; Bandara, R.; Hofmann, G.; Johnson,
R. J. Nat. Prod. 1994, 57, 518.
61. Khalifah, R. G. J. Biol. Chem. 1971, 246, 2561.
62. Kerns, E. H.; Di, L. Drug-like Properties: Concepts, Structure Design and Methods:
from ADME to Toxicity Optimization; Academic Press: London, 2008.
63. Schrödinger. Schrödinger LLC: New York, 2005; http://www.schrodinger.com.
64. Schrödinger. QikProp 3.5 User Manual, Schrödinger Press, 2012.
65. Schultz, T. W.; Rogers, K.; Aptula, A. O. Contact Dermatitis 2009, 60, 21.
66. Wolan, D. W.; Zorn, J. A.; Gray, D. C.; Wells, J. A. Science 2009, 326, 853.
67. Aptula, A. O.; Patlewicz, G.; Roberts, D. W. Chem. Res. Toxicol. 2005, 18, 1420.
